
Cellgen Diagnostics and Genomic Testing Cooperative Partner
CELLGEN DIAGNOSTICS AND GENOMIC TESTING COOPERATIVE PARTNER TO ESTABLISH A NEW STANDARD IN CO-DEVELOPMENT OF COMPANION DIAGNOSTICS FOR CANCER THERAPIES Alliance will enable a faster

CELLGEN DIAGNOSTICS AND GENOMIC TESTING COOPERATIVE PARTNER TO ESTABLISH A NEW STANDARD IN CO-DEVELOPMENT OF COMPANION DIAGNOSTICS FOR CANCER THERAPIES Alliance will enable a faster

Order GTC Hematology Expression/Fusion Profile The GTC Hematology Expression/Fusion test provides actionable information for: 1) Determining Fusion and classification (Ph-Positive or Ph-Like) Acute lymphoblastic

23rd Annual International Congress on Hematologic Malignancies 2019: Focus on Leukemias, Lymphomas and Myeloma The annual International Congress on Hematologic Malignancies is dedicated to

Order GTC Hematology Expression/Fusion Profile GTC Hematology Expression/Fusion Profiling provides highly informative and actionable data for patients with DLBCL as follows: 1) B-cell Markers: This

Order GTC Solid Tumor Expression/Fusion Profile Sarcoma Diagnosis and Classification. The GTC Solid Tumor Expression/Fusion Profiling provides highly informative and actionable data for patients with

A quick interview from Genomic Testing Cooperative founder, CEO/CMO, Dr. Albitar, introducing Genomic Testing Cooperative answering questions about it… Get all the answers by watching

Time Matters on Health Tests When dealing with cancer, clinicians and patients need to know the results of molecular testing as soon as possible. Are

-a step forward to precision in cancer diagnostics- CSI LABORATORIES ADVANCES BY PARTNERING WITH DR. MAHER ALBITAR OF GENOMICS TESTING COOPERATIVE (GTC) Membership in the Co-Op also
Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts The vast majority of

Dr. Albitar’s molecular work is presented at the ASH meeting in oral and poster presentations Eltrombopag Improves Hematopoiesis in Patients with Low to Intermediate-2 Risk